Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Botox And Beyond: Allergan Lays Out Growth Strategy

Executive Summary

With Botox now its biggest product, Allergan highlights moves to further the versatile drug’s expansion into new medical indications, as well as efforts to bolster the company’s traditional ophthalmic core, including advancing a pipeline candidate in the increasingly competitive wet-AMD field.

You may also be interested in...

Allergan Inks Two More Deals With Molecular Partners On New Approach To Ophthalmic Conditions

Allergan licenses a second novel product from Switzerland's Molecular Partners for ophthalmic indications and enters into a discovery alliance under which it has the option to license three further ophthalmic compounds.

Start-Ups, With An Eye On Success In Wet AMD, Tackle The Dry Form

“Early and primitive” is a term frequently used to describe drug development for dry AMD in discussions with experts. Several companies have brought products to Phase II trials, but none has met the efficacy endpoints. A new crop of start-ups is trying, driven by the huge unmet demand and emerging science.

Ipsen Moves Aggressively On U.S. Strategy, Builds Out Commercial and R&D Infrastructure

As part of an ongoing strategic reorganization, Ipsen announced the appointment of a nine-member U.S. leadership team to execute on the growth of its neurology and endocrinology franchises.

Related Content


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts